Meng Ding
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 10%
- Extracellular vesicles in disease
- Circular RNAs in diseases
- RNA modifications and cancer
- RNA Interference and Gene Delivery
Papers in
-
- MicroRNA in disease regulation 13
- Cancer-related molecular mechanisms research 7
- Co-authors
- Heng DongChen‐Yu ZhangYongbin MouCheng WangQiang LiDongliang YangYu ZhangLijun Mao
- Journals
- Advanced Healthcare Materials (4 papers)ACS Nano (3 papers)Oncotarget (3 papers)Advanced Science (3 papers)Cell Death Discovery (2 papers)
- Partner nations
- ChinaSingaporeUnited States
In The Last Decade
Meng Ding
75 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Cancer Research 531
- Molecular Biology 1.0k
- Periodontics 64
- Biomedical Engineering 578
- Nephrology 83
Countries citing papers authored by Meng Ding
This map shows the geographic impact of Meng Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meng Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meng Ding more than expected).
Fields of papers citing papers by Meng Ding
This network shows the impact of papers produced by Meng Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meng Ding. The network helps show where Meng Ding may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Meng Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 22 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 11 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 13 | |
| 8 | 2023 | 62 | |
| 9 | 2023 | 28 | |
| 10 | 2023 | 6 | |
| 11 | 2023 | 5 | |
| 12 | 2022 | 27 | |
| 13 | 2022 | 1 | |
| 14 | 2022 | 4 | |
| 15 | 2022 | 25 | |
| 16 | 2021 | 20 | |
| 17 | 2019 | 104 | |
| 18 | 2018 | 32 | |
| 19 | 2018 | 51 | |
| 20 | 2018 | 18 |
About Meng Ding
Meng Ding is a scholar working on Cancer Research, Orthodontics, Immunology, Periodontics and Molecular Biology, having authored 76 papers that have together received 2.1k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (20 papers), MicroRNA in disease regulation (13 papers), RNA modifications and cancer (10 papers), Advanced Nanomaterials in Catalysis (9 papers), Extracellular vesicles in disease (9 papers), Circular RNAs in diseases (8 papers), Cancer-related molecular mechanisms research (7 papers) and Immunotherapy and Immune Responses (5 papers). The work is most often cited by research in Cancer Research (531 citations), Molecular Biology (1.0k citations), Periodontics (64 citations), Biomedical Engineering (578 citations) and Nephrology (83 citations). Meng Ding has collaborated with scholars based in China, Singapore and United States. Frequent co-authors include Heng Dong, Chen‐Yu Zhang, Yongbin Mou, Cheng Wang, Qiang Li, Dongliang Yang, Yu Zhang, Lijun Mao, Chunhua Yang and Ke Zen. Their work appears in journals such as Advanced Healthcare Materials, ACS Nano, Oncotarget, Advanced Science and Cell Death Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.